In its recall notification sent on May 16, BD confirmed that an incomplete occlusion can occur on the pumping segment of certain Alaris Pump Model 8100 infusion sets due to a variation in the wall ...

FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...

The FDA designated BD’s recall of its infusion pump ... It has been selling the Alaris pump under a consent decree till 2023, except for intravenous administration sets and accessories.

Researchers at healthcare security firm CyberMDX found two vulnerabilities in the Alaris Gateway Workstation, developed by medical device maker Becton Dickinson. Infusion pumps are one of the most ...

Since the start of 2020, BD’s Alaris infusion pumps have been the subject of more ... Smiths Medical warns infusion set issues could cause false alarms, underdelivery The new green light comes ...

The FDA granted 510(k) clearance to Becton Dickinson’s updated Alaris infusion pump, allowing the company to resume distribution of its system while remediating or replacing older Alaris devices ...

To data, there have been 13 reported injuries. Becton Dickinson (BD)/Carefusion 303 is recalling the Alaris infusion pump due to incompatibility issues with Cardinal Health Monoject syringes.

BD issues cybersecurity alert for hacking risk found in Alaris infusion pump monitoring ... to flow into the administration set, which connects the pump to the patient. If that happens, the ...

over allegations it misled investors about risks associated with its Alaris infusion pump. The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges ...